628 related articles for article (PubMed ID: 14519594)
1. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
2. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
Dai C; Yang J; Bastacky S; Xia J; Li Y; Liu Y
J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
[TBL] [Abstract][Full Text] [Related]
3. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor suppresses transforming growth factor-beta-1 and type III collagen in human primary renal fibroblasts.
Mou S; Wang Q; Shi B; Gu L; Ni Z
Kaohsiung J Med Sci; 2009 Nov; 25(11):577-87. PubMed ID: 19858036
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
6. Influence of C-peptide on early glomerular changes in diabetic mice.
Maezawa Y; Yokote K; Sonezaki K; Fujimoto M; Kobayashi K; Kawamura H; Tokuyama T; Takemoto M; Ueda S; Kuwaki T; Mori S; Wahren J; Saito Y
Diabetes Metab Res Rev; 2006; 22(4):313-22. PubMed ID: 16389646
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.
Inoue T; Okada H; Kobayashi T; Watanabe Y; Kanno Y; Kopp JB; Nishida T; Takigawa M; Ueno M; Nakamura T; Suzuki H
FASEB J; 2003 Feb; 17(2):268-70. PubMed ID: 12475893
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
Daniel C; Schaub K; Amann K; Lawler J; Hugo C
Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
[TBL] [Abstract][Full Text] [Related]
9. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
[TBL] [Abstract][Full Text] [Related]
10. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
Hamada Y; Fukagawa M
Kobe J Med Sci; 2007; 53(1-2):53-61. PubMed ID: 17582205
[TBL] [Abstract][Full Text] [Related]
11. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide.
Yuan P; Xue H; Zhou L; Qu L; Li C; Wang Z; Ni J; Yu C; Yao T; Huang Y; Wang R; Lu L
Nephrol Dial Transplant; 2011 Jul; 26(7):2119-26. PubMed ID: 21208996
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of moderately elevated blood glucose and locally produced TGF-beta1 on glomerular morphology and renal collagen production.
Krag S; Nyengaard JR; Wogensen L
Nephrol Dial Transplant; 2007 Sep; 22(9):2485-96. PubMed ID: 17452404
[TBL] [Abstract][Full Text] [Related]
13. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
Seo JY; Park J; Yu MR; Kim YS; Ha H; Lee HB
Am J Nephrol; 2009; 30(6):481-90. PubMed ID: 19786738
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor alpha-mediated events promote sex-specific diabetic glomerular hypertrophy.
Lovegrove AS; Sun J; Gould KA; Lubahn DB; Korach KS; Lane PH
Am J Physiol Renal Physiol; 2004 Sep; 287(3):F586-91. PubMed ID: 15149972
[TBL] [Abstract][Full Text] [Related]
15. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease.
Mizuno S; Kurosawa T; Matsumoto K; Mizuno-Horikawa Y; Okamoto M; Nakamura T
J Clin Invest; 1998 May; 101(9):1827-34. PubMed ID: 9576745
[TBL] [Abstract][Full Text] [Related]
17. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
[TBL] [Abstract][Full Text] [Related]
18. Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy.
Ju KD; Shin EK; Cho EJ; Yoon HB; Kim HS; Kim H; Yang J; Hwang YH; Ahn C; Oh KH
Am J Physiol Renal Physiol; 2012 Mar; 302(5):F606-13. PubMed ID: 22129969
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
20. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
